End-Stage Renal Disease (ESRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

End-Stage Renal Disease (ESRD) Market Outlook

Thelansis’s “End-Stage Renal Disease (ESRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential End-Stage Renal Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

End-Stage Renal Disease (ESRD) Overview

End-stage renal disease (ESRD) represents the irreversible phase of kidney dysfunction that cannot be effectively managed through conservative measures alone, necessitating either dialysis or kidney transplantation for survival. There are two primary forms of kidney impairment leading to ESRD: acute and chronic. Chronic renal failure (CRF), which signifies ESRD, denotes a level of kidney dysfunction (i.e., glomerular filtration rate, GFR<10–12 mL/min) where sustaining life without dialysis becomes untenable in the long term. In contrast to acute kidney failure, chronic kidney failure is a permanent condition characterized by a gradual deterioration in renal function. Once established, kidney function cannot be restored even after addressing the initial triggering factors. CRF may persist for 10 to 20 years before progressing to ESRD. Prolonged diabetes mellitus or hypertension accounts for over 70% of cases of advanced chronic kidney disease, while glomerulonephritis, cystic diseases, and other urologic conditions contribute to another 12%. The remaining 15% have either unknown causes or arise from different conditions. Chronic kidney disease (CKD) entails a substantially elevated risk of morbidity and mortality from cardiovascular diseases compared to the general population. Cardiovascular-related deaths make up 45% of all fatalities among dialysis patients, with 80% to 90% of CKD patients succumbing to cardiovascular ailments before requiring dialysis. The precise biological mechanisms underlying this phenomenon remain unclear. However, factors such as the uremic environment, coexisting comorbidities, and reluctance to conduct investigative procedures in CKD patients may play significant roles.

• CKD affects an estimated 35.5 million adults in the US, representing approximately 14% of the population. As many as 9 out of 10 individuals are unaware of their condition; furthermore, approximately 1 in 3 adults with severe CKD remain undiagnosed.
• CKD prevalence is higher among individuals aged 65 years or older (34%) compared to those aged 45–64 years (12%) or 18–44 years (6%).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2024-2034

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: